Pellicelli AM, D’Ambrosio C, Dessanti ML, Villani R, Fondacaro L, Miglioresi L, Grillo LR, Andreoli A

Language: English
References: 24
Page: 756-761
PDF size: 168.78 Kb.

ABSTRACT

Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.

REFERENCES

1. Narang TK, Ahrens W, Russo MW. Post liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-35.

2. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrel L. Cholestatic hepatitis C in liver allograft. Liver Transpl Surg 1998; 4: 304-10.

3. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically- proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011; 41: 328-39.

4. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large Bcell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-25.

5. Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 2011; 3: 278-84.

6. Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, di Fonzo M, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011; 43: 139-42.

7. McCaughan GW, Bowen DG. Pathogenesis of cholestatic hepatitis C. J Hepatol. 2011; 54: 392-94.

8. Torres H A, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-66.

9. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8.

10. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol 2006; 24: 953-60.

11. El Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer 1984; 54: 2006-08.

12. Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3: 588.

13. Aviles A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108: 912-3.

14. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma 2009; 50: 1083-95.

15. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10.

16. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.Eur J Haematol 2005; 74: 158-65

17. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20- positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008; 83: 59-62.

18. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol 2010; 85: 46-50.

19. Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014; 99: 489-96.

20. Cunningham-Rundles C,Lieberman P, Hellman G, Chaganti RS. Non Hodgkin lymphoma in common variable immunodeficiency. Am J Hematol 1991; 37: 69-74.

21. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002; 16: 61-4.

22. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-05.

23. Rossotti R, Travi G, Pazzi AM, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015; 62: 234-37.

24. Lyman GH, Dale DC, Friedberg J, Crawford, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-11.